FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894090142> ?p ?o ?g. }

• W2894090142 endingPage "295" @default.
• W2894090142 startingPage "283" @default.
• W2894090142 abstract "Purpose To evaluate the comparative effectiveness of 3 regional corticosteroid injections for uveitic macular edema (ME): periocular triamcinolone acetonide (PTA), intravitreal triamcinolone acetonide (ITA), and the intravitreal dexamethasone implant (IDI). Design Multicenter, randomized clinical trial. Participants Patients with uveitic ME. Methods Patients were randomized 1:1:1 to receive 1 of the 3 therapies. Patients with bilateral ME were assigned the same treatment for both eyes. Main Outcome Measures The primary outcome was the proportion of baseline (PropBL) central subfield thickness (CST) at 8 weeks (CST at 8 weeks/CST at baseline) assessed with OCT by masked readers. Secondary outcomes included ≥20% improvement and resolution of ME, best-corrected visual acuity (BCVA), and intraocular pressure (IOP) events over 24 weeks. Results All treatment groups demonstrated improved CST during follow-up. At 8 weeks, each group had clinically meaningful reductions in CST relative to baseline (PropBL: 0.77, 0.61, and 0.54, respectively, which translates to reductions of 23%, 39%, and 46% for PTA, ITA, and IDI, respectively). Intravitreal triamcinolone acetonide (PropBL ITA/PropBL PTA, hazard ratio [HR], 0.79; 99.87% confidence interval [CI], 0.65–0.96) and IDI (PropBL IDI/PropBL PTA, HR, 0.69; 99.87% CI, 0.56–0.86) had larger reductions in CST than PTA (P < 0.0001). Intravitreal dexamethasone implant was noninferior to ITA at 8 weeks (PropBL IDI/PropBL ITA, HR, 0.88; 99.87% CI, 0.71–1.08). Both ITA and IDI treatments also were superior to PTA treatment in improving and resolving uveitic ME. All treatment groups demonstrated BCVA improvement throughout follow-up. Both ITA and IDI groups had improvements in BCVA that was 5 letters greater than in the PTA group at 8 weeks (P < 0.004). The risk of having IOP ≥24 mmHg was higher in the intravitreal treatment groups compared with the periocular group (HR, 1.83; 95% CI, 0.91–3.65 and HR, 2.52; 95% CI, 1.29–4.91 for ITA and IDI, respectively); however, there was no significant difference between the 2 intravitreal treatment groups. Conclusions Intravitreal triamcinolone acetonide and the IDI were superior to PTA for treating uveitic ME with modest increases in the risk of IOP elevation. This risk did not differ significantly between intravitreal treatments. To evaluate the comparative effectiveness of 3 regional corticosteroid injections for uveitic macular edema (ME): periocular triamcinolone acetonide (PTA), intravitreal triamcinolone acetonide (ITA), and the intravitreal dexamethasone implant (IDI). Multicenter, randomized clinical trial. Patients with uveitic ME. Patients were randomized 1:1:1 to receive 1 of the 3 therapies. Patients with bilateral ME were assigned the same treatment for both eyes. The primary outcome was the proportion of baseline (PropBL) central subfield thickness (CST) at 8 weeks (CST at 8 weeks/CST at baseline) assessed with OCT by masked readers. Secondary outcomes included ≥20% improvement and resolution of ME, best-corrected visual acuity (BCVA), and intraocular pressure (IOP) events over 24 weeks. All treatment groups demonstrated improved CST during follow-up. At 8 weeks, each group had clinically meaningful reductions in CST relative to baseline (PropBL: 0.77, 0.61, and 0.54, respectively, which translates to reductions of 23%, 39%, and 46% for PTA, ITA, and IDI, respectively). Intravitreal triamcinolone acetonide (PropBL ITA/PropBL PTA, hazard ratio [HR], 0.79; 99.87% confidence interval [CI], 0.65–0.96) and IDI (PropBL IDI/PropBL PTA, HR, 0.69; 99.87% CI, 0.56–0.86) had larger reductions in CST than PTA (P < 0.0001). Intravitreal dexamethasone implant was noninferior to ITA at 8 weeks (PropBL IDI/PropBL ITA, HR, 0.88; 99.87% CI, 0.71–1.08). Both ITA and IDI treatments also were superior to PTA treatment in improving and resolving uveitic ME. All treatment groups demonstrated BCVA improvement throughout follow-up. Both ITA and IDI groups had improvements in BCVA that was 5 letters greater than in the PTA group at 8 weeks (P < 0.004). The risk of having IOP ≥24 mmHg was higher in the intravitreal treatment groups compared with the periocular group (HR, 1.83; 95% CI, 0.91–3.65 and HR, 2.52; 95% CI, 1.29–4.91 for ITA and IDI, respectively); however, there was no significant difference between the 2 intravitreal treatment groups. Intravitreal triamcinolone acetonide and the IDI were superior to PTA for treating uveitic ME with modest increases in the risk of IOP elevation. This risk did not differ significantly between intravitreal treatments." @default.
• W2894090142 created "2018-10-05" @default.
• W2894090142 creator A5004953489 @default.
• W2894090142 creator A5006274430 @default.
• W2894090142 creator A5044270602 @default.
• W2894090142 creator A5049898786 @default.
• W2894090142 creator A5057101748 @default.
• W2894090142 creator A5057198644 @default.
• W2894090142 creator A5062196360 @default.
• W2894090142 creator A5082563606 @default.
• W2894090142 creator A5091117608 @default.
• W2894090142 date "2019-02-01" @default.
• W2894090142 modified "2023-10-17" @default.
• W2894090142 title "Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema" @default.
• W2894090142 cites W1540697174 @default.
• W2894090142 cites W166656028 @default.
• W2894090142 cites W1719749797 @default.
• W2894090142 cites W1865261266 @default.
• W2894090142 cites W1965902362 @default.
• W2894090142 cites W1969307963 @default.
• W2894090142 cites W1979294470 @default.
• W2894090142 cites W1979447309 @default.
• W2894090142 cites W1979534828 @default.
• W2894090142 cites W1991049779 @default.
• W2894090142 cites W1992445417 @default.
• W2894090142 cites W1994741767 @default.
• W2894090142 cites W1995086395 @default.
• W2894090142 cites W2018739587 @default.
• W2894090142 cites W2047505247 @default.
• W2894090142 cites W2050766359 @default.
• W2894090142 cites W2051056980 @default.
• W2894090142 cites W2053930044 @default.
• W2894090142 cites W2056287065 @default.
• W2894090142 cites W2057725744 @default.
• W2894090142 cites W2058660748 @default.
• W2894090142 cites W2058913110 @default.
• W2894090142 cites W2063554932 @default.
• W2894090142 cites W2063977196 @default.
• W2894090142 cites W2064705195 @default.
• W2894090142 cites W2079217070 @default.
• W2894090142 cites W2080252748 @default.
• W2894090142 cites W2081662709 @default.
• W2894090142 cites W2082186503 @default.
• W2894090142 cites W2085681324 @default.
• W2894090142 cites W2087762421 @default.
• W2894090142 cites W2132561513 @default.
• W2894090142 cites W2135298947 @default.
• W2894090142 cites W2135333970 @default.
• W2894090142 cites W2135897976 @default.
• W2894090142 cites W2156177816 @default.
• W2894090142 cites W2165265638 @default.
• W2894090142 cites W2166108068 @default.
• W2894090142 cites W2170347817 @default.
• W2894090142 cites W2290004705 @default.
• W2894090142 cites W2417921379 @default.
• W2894090142 cites W2470948656 @default.
• W2894090142 cites W34961135 @default.
• W2894090142 doi "https://doi.org/10.1016/j.ophtha.2018.08.021" @default.
• W2894090142 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6348060" @default.
• W2894090142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30269924" @default.
• W2894090142 hasPublicationYear "2019" @default.
• W2894090142 type Work @default.
• W2894090142 sameAs 2894090142 @default.
• W2894090142 citedByCount "122" @default.
• W2894090142 countsByYear W28940901422019 @default.
• W2894090142 countsByYear W28940901422020 @default.
• W2894090142 countsByYear W28940901422021 @default.
• W2894090142 countsByYear W28940901422022 @default.
• W2894090142 countsByYear W28940901422023 @default.
• W2894090142 crossrefType "journal-article" @default.
• W2894090142 hasAuthorship W2894090142A5004953489 @default.
• W2894090142 hasAuthorship W2894090142A5006274430 @default.
• W2894090142 hasAuthorship W2894090142A5044270602 @default.
• W2894090142 hasAuthorship W2894090142A5049898786 @default.
• W2894090142 hasAuthorship W2894090142A5057101748 @default.
• W2894090142 hasAuthorship W2894090142A5057198644 @default.
• W2894090142 hasAuthorship W2894090142A5062196360 @default.
• W2894090142 hasAuthorship W2894090142A5082563606 @default.
• W2894090142 hasAuthorship W2894090142A5091117608 @default.
• W2894090142 hasBestOaLocation W28940901422 @default.
• W2894090142 hasConcept C118487528 @default.
• W2894090142 hasConcept C126322002 @default.
• W2894090142 hasConcept C141071460 @default.
• W2894090142 hasConcept C168563851 @default.
• W2894090142 hasConcept C207103383 @default.
• W2894090142 hasConcept C2776251621 @default.
• W2894090142 hasConcept C2776804153 @default.
• W2894090142 hasConcept C2778257484 @default.
• W2894090142 hasConcept C2778903070 @default.
• W2894090142 hasConcept C2780347916 @default.
• W2894090142 hasConcept C2780401358 @default.
• W2894090142 hasConcept C2781092963 @default.
• W2894090142 hasConcept C2781411149 @default.
• W2894090142 hasConcept C44249647 @default.
• W2894090142 hasConcept C71924100 @default.
• W2894090142 hasConceptScore W2894090142C118487528 @default.
• W2894090142 hasConceptScore W2894090142C126322002 @default.
• W2894090142 hasConceptScore W2894090142C141071460 @default.

• next